Sara Bouberhan

What was reported, 2019–2025

$111

General payments

3 separate payments. What they were, as CMS records them, is below.

$4,335

Research payments

Funding for a study, usually paid to an institution with this doctor named on it. Not added to general payments, and not income.

$0

Ownership and investment

The value of a stake this doctor or an immediate family member held.

0

Disputed

This doctor has contested none of the payments reported about them.

How this compares

General payments: $111, 2019–⁠2025

By the amount companies reported, 10,535th among the 11,988 profiles with general payments in Hematology & Oncology.

General payments: this profile's rank in each group, its place among the profiles nationally and its share of the national total

Nationally	1,211,736th of 1,688,859
In Massachusetts	27,133rd of 40,422
In Hematology & Oncology	10,535th of 11,988
Profiles below it nationally	More than 28%
Share of the national total	< 0.1%

Research payments: $4,335, 2019–⁠2025

By the amount companies reported, 671st among the 1,404 profiles named on research payments in Hematology & Oncology.

Research payments: this profile's rank in each group, its place among the profiles nationally and its share of the national total

Nationally	10,141st of 22,827
In Massachusetts	529th of 1,067
In Hematology & Oncology	671st of 1,404
Profiles below it nationally	More than 55%
Share of the national total	< 0.1%

What the payments were

Each payment as the manufacturer categorized it when reporting it to CMS, across 2019–2025. Together they are the general payments above. A category is the reporter’s, and nothing in the record says a payment in any of them was improper.

By program year

CMS reports a program year at a time and also publishes its own total across them, which is what the figures above are. These rows are that total taken apart, not a second set of payments.

CMS’s file covers 2019–2025. It holds no payments to Sara Bouberhan in 2019–2020.

The record

National Provider Identifier

1487929634

The identifier this page is addressed by, and the one both CMS files share.

Specialty

Hematology & Oncology

Allopathic & Osteopathic Physicians, in CMS's taxonomy.

Licensed in

CT

The state of the license CMS lists first.

Recipient type

Covered Recipient Physician

How CMS classifies the recipient of these payments.

Medicare prescribing

What this provider billed to Medicare Part D in 2024, as CMS published it. Medicare Part D only: what they prescribed outside it is not here.

617

Claims

Prescriptions and refills billed to Part D, as CMS counts them.

$766,401

Total drug cost

What Part D, the plan and the patient paid together. Not what this provider was paid — they are paid nothing out of it.

104

Beneficiaries

People with at least one prescription from this provider.

116

Brand-name claims

Of the claims above, those for a brand-name drug.

501

Generic claims

Of the claims above, those for a generic.

43

Opioid claims

CMS puts this provider's opioid prescribing rate at 6.9692058346839545% of their claims. That is their figure, computed from their own unsuppressed data.

19

Antibiotic claims

Claims for an antibiotic.

Hematology-Oncology

Prescriber type

As CMS classifies this prescriber. Credentials: MD.

A blank is not a zero. CMS withholds a value between 1 and 10, and withholds the next lowest alongside it so the first cannot be worked out by subtraction — so a withheld figure is not even evidence that the number was small. Rows for ten or fewer claims are removed from the file altogether, which is why the parts of a total can be withheld while the total is published.

Elsewhere

• Payments to doctors in Massachusetts — what was reported across the state this doctor practises in.
• What drug and device companies pay doctors — the national picture these figures are part of.
• This record at CMS — the publisher’s own page for this profile.
• The NPI registry — who this identifier belongs to, at CMS.